Details for Patent: 10,076,514

Which drugs does patent 10,076,514 protect, and when does it expire?

Patent 10,076,514 protects GALAFOLD and is included in one NDA.

This patent has sixteen patent family members in six countries.

Summary for Patent: 10,076,514

Title:	Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Abstract:	Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing .alpha.-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for .alpha.-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding .alpha.-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
Inventor(s):	Benjamin; Elfrida (Millstone Township, NJ)
Assignee:	Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:	15/459,149
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,076,514
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 10,076,514

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes						THE TREATMENT OF FABRY PATIENTS

International Family Members for US Patent 10,076,514

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	109069494
China	114159436
European Patent Office	3432882